Gene therapies are revolutionizing the therapeutic landscape for rare and inherited diseases. For the field to progress, however, there are several unique and complex challenges. Perhaps the most prominent of these challenges is the immune response to gene therapy delivery.

The inaugural Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better measure, modulate and predict immune response to your gene therapy candidate.

Uniting industry leaders across the gene therapy space, this multi-disciplinary forum will enable you to develop more effective and safe gene therapies by discussing how you can:

• Identify and tailor novel capsid proteins for more specific targeting and immunologic evasion
• Reduce AAV neutralizing antibodies
• Confidently assess immunosuppression strategies to dampen immune response

As the only conference dedicated to the immunogenicity of gene therapies, this will be an unrivalled opportunity to join 80+ like-minded thought-leaders from cross-disciplines to foster new connections and partnerships.

Download the full event guide to learn more from companies including BioMarin, Spark Therapeutics and Novartis.